Page 116 - தொழிற்சங்கம் அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Minuscule risk of blood clots with Covishield, no clots yet with Covaxin: Expert panel

Minuscule risk of blood clots with Covishield, no clots yet with Covaxin: Expert panel The risk factor discovered by the committee in India is lower than the four cases per million found among those given Astrazeneca jabs in the UK. Share Via Email | A+A A- By Express News Service NEW DELHI: A very minuscule but definitive risk of thromboembolic (blood clot) events 0.61 cases per million vaccinations has been seen among those administered the Covishield vaccine in India, the National Adverse Events Following Immunisation (AEFI) committee has said in a report to the Ministry of Health and Family Welfare.

United kingdomShahid jameelNational adverse events following immunisationUnion ministry of healthHealth regulatory authorityMinistry of healthAdvisor to centre covidNews serviceHealth ministryExpress newsUnion ministryChief advisorSoutheast asianCovishield riskOvishield blood clot riskOvishield aefi

Covid-19 | Remdesivir production stepped up, Centre tells Madras High Court

Centre tells Madras HC that production capacity of 7 manufacturers enhanced

United statesTamil naduJustice sanjib banerjeeTeva pharmaJustice senthilkumar ramamoorthyDepartment of pharmaceuticalsCentre onHonour labUnion ministry of healthMadras high courtMinistry of external affairsDivision benchDrugs controller generalChief justice sanjib banerjeeAdditional solicitor generalDirectorate general

Count Of Ventilators In India s Public Hospitals Triples Since The Onset Of COVID-19 Pandemic

About 43,800 new ventilators have been supplied to the States and the UTs since the onset of the pandemic last year.

Uttar pradeshUnion ministry of healthUnion territories utsUnion territoriesUnion ministryCovid 19Pm cares fundஉத்தர் பிரதேஷ்தொழிற்சங்கம் அமைச்சகம் ஆஃப் ஆரோக்கியம்தொழிற்சங்கம் பிரதேசங்கள் அட்ஸ்தொழிற்சங்கம் பிரதேசங்கள்தொழிற்சங்கம் அமைச்சகம்பீயெம் அக்கறை நிதி

Remdesivir production increased from 38 80 lakh to 1 19 crore vials a month, Centre tells HC

‘Export of the drug has been prohibited and it is also being imported from Egypt’ The Centre on Monday told the Madras High Court that seven Indian licensees of patented anti-viral drug Remdesivir were manufacturing only 27 lakh vials a month as on April 1 this year, though their installed capacity was 38.80 lakh a month. Now, due to the surge in COVID-19 cases in certain parts of the country, the Drugs Controller General of India (DCGI) has permitted them to produce as many as 1.19 crore vials a month. Appearing before the first Division Bench of Chief Justice Sanjib Banerjee and Justice Senthilkumar Ramamoorthy, Additional Solicitor General (ASG) R. Sankaranarayanan said the patent for Remdesivir was held by Gilead of the United States and only seven Indian companies were manufacturing the drug here, under license agreements. DCGI V.G. Somani jumped into action when the demand for the drug increased recently.

United statesTamil naduJustice sanjib banerjeeTeva pharmaJustice senthilkumar ramamoorthyDepartment of pharmaceuticalsCentre onHonour labUnion ministry of healthMadras high courtMinistry of external affairsDivision benchDrugs controller generalChief justice sanjib banerjeeAdditional solicitor generalDirectorate general

കോവിന്‍ പോര്‍ട്ടല്‍ ഹിന്ദിയിലും 14 പ്രാദേശികഭാഷകളിലും; വകഭേദങ്ങളെക്കുറിച്ച് പഠിക്കാന്‍ ലാബുകള്‍

കോവിന്‍ പോര്‍ട്ടല്‍ ഹിന്ദിയിലും 14 പ്രാദേശികഭാഷകളിലും; വകഭേദങ്ങളെക്കുറിച്ച് പഠിക്കാന്‍ ലാബുകള്‍
mathrubhumi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mathrubhumi.com Daily Mail and Mail on Sunday newspapers.

Union healthUnion ministry of healthUnion ministryதொழிற்சங்கம் ஆரோக்கியம்தொழிற்சங்கம் அமைச்சகம் ஆஃப் ஆரோக்கியம்தொழிற்சங்கம் அமைச்சகம்